A box containing vials of Bharat Biotech’s Covaxin vaccine for coronavirus at Sanjeevan Hospital in Daryaganj, New Delhi. (Photographer. T. Narayan/Bloomberg)
5 years ago
Mar 04, 2021
Follow the developments around the Covid-19 outbreak here.
Total number of confirmed coronavirus cases: 1,11,56,923
Active cases: 1,73,413
Cured/discharged/migrated: 1,08,26,075
Deaths: 1,57,435
Fresh cases in the last 24 hours: 17,407
One-day recoveries: 14,031
One-day deaths: 89
India has administered 1,66,16,048 vaccine shots, with nearly 10 lakh of them given to the elderly in the last 24 hours.
Prime Minister Narendra Modi kicked off the second phase of immunisations on Monday — where senior citizens and those above the age of 45 with comorbidities will be able to get inoculated — by taking the first dose of Covaxin.
The indigenous vaccine, which was co-developed by Hyderabad-based Bharat Biotech International Ltd. and the Indian Council of Medical Research, showed an efficacy rate of 81% in those without prior infection after a second dose, the company said in a statement Wednesday. That’s better than Bharat Biotech’s guidance last year of around 60% and the country’s benchmark of 50% for vaccines targeting the novel coronavirus.
The interim analysis cements Bharat Biotech’s claims of the vaccine being safe and may help overcome vaccine hesitancy in the country. The data is also a rebuttal for critics who had questioned the unprecedented haste with which the shot was approved in early January and deployed among India’s frontline health care workers even before providing any Phase 3 trial data.
